Immune Response Modifier Conjugates with Labile Bonds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune response modifiers (IRMs) face limitations in therapeutic applications due to reduced activity when chemical substitutions are made at specific sites, necessitating the development of IRM conjugates with labile bonds to regenerate active IRM compounds in targeted locations.
Innovation Solution
The creation of IRM conjugates with a covalently linked second active moiety and a labile bond that is cleaved in specific environments, such as tumors, to release the active IRM compound, allowing for localized and controlled immune response induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical substitution is made at specific sites of IRM compounds, then the activity of IRM compounds is decreased or eliminated, but this substitution is necessary to enable conjugate formation
Solution Approach 1:
The IRM compound is divided into two parts: an IRM moiety that retains immunomodulatory activity and a substitution site that enables conjugate formation. The substitution at specific sites (such as the 6-position of imidazoquinoline) allows attachment to polymers or other moieties while the core IRM structure remains intact to maintain biological activity.
Solution Approach 2:
A polymer or other moiety acts as an intermediary carrier that transports the IRM compound to the target site. The conjugate structure serves as a mediator between the delivery system and the active IRM moiety, enabling targeted delivery while preserving the immunomodulatory function through careful selection of substitution positions.
2Ease of operation
If IRM compounds are administered systemically, then they can reach target sites, but they induce unwanted systemic immune responses
Solution Approach 1:
The conjugate structure enables localized release of active IRM compounds at the target site. The polymer carrier provides targeted delivery to specific tissues or cells, and the controlled release mechanism ensures that immunomodulatory activity is concentrated where needed rather than distributed systemically, reducing off-target effects.
Solution Approach 2:
The active IRM moiety is extracted from the conjugate structure at the target site through cleavage of the labile bond. This extraction occurs locally at the destination rather than through systemic distribution, allowing the active compound to be released only where the conjugate accumulates, thereby minimizing systemic exposure and unwanted immune responses.
3Reliability
If IRM compounds are conjugated to polymers, then therapeutic index is increased, but the molecular weight and complexity increase
Solution Approach 1:
The invention creates a composite structure combining the small molecule IRM compound with a polymer carrier. This composite conjugate leverages the benefits of both components: the polymer provides targeted delivery and controlled release capabilities while the IRM moiety maintains its immunomodulatory activity. The composite structure increases therapeutic index by enhancing target-site concentration and reducing systemic toxicity.
Solution Approach 2:
The polymer carrier serves multiple functions: it acts as a delivery vehicle, provides targeting capability, enables controlled release through labile bond cleavage, and can be designed with various functional groups for different applications. This multi-functionality justifies the increased molecular complexity by providing numerous benefits that improve therapeutic outcomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the therapeutic efficacy of IRMs by maintaining their activity until they reach the target site, reducing systemic immune responses and increasing the therapeutic index, thereby expanding their therapeutic benefits.
Implementation Method 1
the covalent link comprises a labile bond directly attached to the IRM moiety
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.